ASCO 2015 - CheckMate 067: Improved PFS with Nivolumab (N) + Ipilimumab (I) vs N vs I in metastatic melanoma (in 2 slides)

ASCO 2015
The results of the CheckMate 067 trial were presented. In this trial patients with metastatic melanoma enrolled in the Nivolumab + Ipilimumab arm displayed superior PFS compared to Nivolumab and to Ipilimumab arms. The greatest benefit was observed in the low-PD-L1 expression (publication in the NEJM)